Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Headline outcomes only

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 3 · 37.5%High 3 · 37.5%

Stroke · preventing early recurrence after ischaemic stroke or TIA

Dual probably leads to lower stroke compared with one antiplatelet agent (moderate certainty).

1 finding from 1 review

Deaths due to vascular events · preventing early recurrence after ischaemic stroke or TIA

Dual showed no clear difference in vascular death compared with one antiplatelet agent (moderate certainty).

1 finding from 1 review

Myocardial infarction · preventing early recurrence after ischaemic stroke or TIA

Dual showed no clear difference in myocardial infarction compared with one antiplatelet agent (high certainty).

1 finding from 1 review

Stroke, myocardial infarction, or vascular death · preventing early recurrence after ischaemic stroke or TIA

Dual probably leads to lower stroke, myocardial infarction, or vascular death compared with one antiplatelet agent (moderate certainty).

1 finding from 1 review

Intracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA

Dual showed no clear difference in intracranial haemorrhage compared with one antiplatelet agent (low certainty).

1 finding from 1 review

Extracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA

Dual leads to higher extracranial haemorrhage compared with one antiplatelet agent (high certainty).

1 finding from 1 review

Ischaemic stroke · preventing early recurrence after ischaemic stroke or TIA

Dual leads to lower ischaemic stroke compared with one antiplatelet agent (high certainty).

1 finding from 1 review

Outcomes at ≥ 3 months · preventing early recurrence after ischaemic stroke or TIA

The review found no eligible studies for this question.

1 finding from 1 review